Estimating dopamine d2 receptor occupancy for doses of 8 antipsychotics: A meta-analysis

Journal of Clinical Psychopharmacology

Volumn 33, Issue 5, 2013, Pages 675-681

  Lako, Irene M ^a   Van Den Heuvel, Edwin R ^a   Knegtering, Henrikus ^a   Bruggeman, Richard ^a   Taxis, Katja ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; DRD2 PROTEIN, HUMAN; PROTEIN BINDING;

COMPARATIVE STUDY; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG RECEPTOR BINDING; EXPLANATORY VARIABLE; EXTRAPYRAMIDAL SYMPTOM; GATED SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; HUMAN; MENTAL INSTABILITY; META ANALYSIS; MICHAELIS MENTEN KINETICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; REVIEW; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMATIC REVIEW; ADULT; BRAIN; CHEMICALLY INDUCED; DRUG EFFECTS; EMOTION; EXTRAPYRAMIDAL SYNDROME; FEMALE; MALE; METABOLISM; NONLINEAR SYSTEM; SCINTISCANNING; TREATMENT OUTCOME; YOUNG ADULT; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; PROTEIN BINDING;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BRAIN; DOPAMINE ANTAGONISTS; DOPAMINE D2 RECEPTOR ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EMOTIONS; FEMALE; HUMANS; MALE; NONLINEAR DYNAMICS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84883808702     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182983ffa     Document Type: Review

References (44)

1. Jones HM, Pilowsky LS. Dopamine and antipsychotic drug action revisited. Br J Psychiatry. 2002;181:271-275
2. Nordstrom AL, Farde L,Wiesel FA, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients. Biol Psychiatry. 1993;33:227-235
3. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157: 514-520
4. Pilowsky LS, Costa DC, Ell PJ, et al. Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet. 1992;340:199-202
5. Seeman P, Tallerico T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry. 1998;3:123-134
6. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry. 2001;158:360-369
7. Kapur S, Remington G, Zipursky RB, et al. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: A PET study. Life Sci. 1995;57:103-107
8. de Haan L, Lavalaye J, Linszen D, et al. Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am J Psychiatry. 2000;157: 1019-1020
9. Mizrahi R, Rusjan P, Agid O, et al. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: A PET study in schizophrenia. Am J Psychiatry. 2007;164: 630-637
10. Lataster J, van Os J, de Haan L, et al. Emotional experience and estimates of D(2) receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: An experience sampling study. J Clin Psychiatry. 2011;72:1397-1404
11. Nord M, Farde L. Antipsychotic Occupancy of dopamine receptors in schizophrenia. CNS Neurosci Ther. 2011;17:97-103
12. Sparshatt A, Taylor D, Patel MX, et al. AmisulprideVdose, plasma concentration, occupancy and response: Implications for therapeutic drug monitoring. Acta Psychiatr Scand. 2009;120:416-428
13. Uchida H, Takeuchi H, Graff-Guerrero A, et al. Predicting dopamine d2 receptor occupancy from plasma levels of antipsychotic drugs: A systematic review and pooled analysis. J Clin Psychopharmacol. 2011;31:318-325
14. Uchida H, Takeuchi H, Graff-Guerrero A, et al. Dopamine D2 receptor occupancy and clinical effects: A systematic review and pooled analysis. J Clin Psychopharmacol. 2011;31:497-502
15. Stone JM, Davis JM, Leucht S, et al. Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugsVan original patient data meta-Analysis of the SPECT and PET in vivo receptor imaging literature. Schizophr Bull. 2009;35:789-797
16. De Greef R, Maloney A, Olsson-Gisleskog P, et al. Dopamine d(2) occupancy as a biomarker for antipsychotics: Quantifying the relationship with efficacy and extrapyramidal symptoms. AAPS J. 2011;13:121-130
17. Hall H, Sedvall G, Magnusson O, et al. Distribution of D1-And D2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology. 1994;11:245-256
18. Frankle WG. Neuroreceptor imaging studies in schizophrenia. Harv Rev Psychiatry. 2007;15:212-232
19. Weinberger DR, Laruelle M. Neurochemical and neuropharmacological imaging in schizophrenia. In: Davis KL, Charney DS, Coyle JT, et al, eds. NeuropharmacologyVthe Fifth Generation of Progress. Philadelphia, PA: Lippincott, Williams & Wilkins; 2001
20. Kapur S, Zipursky RB, Remington G, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: A PET investigation. Am J Psychiatry. 1998;155:921-928
21. Catafau AM, Penengo MM, Nucci G, et al. Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. J Psychopharmacol. 2008;22:882-894
22. Kim E, Howes OD, Yu KS, et al. Calculating occupancy when one does not have baseline: A comparison of different options. J Cereb Blood Flow Metab. 2011;31:1760-1767
23. Seber G, Wild C. Nonlinear Regression. New York, NY: Wiley; 2003
24. Vonesh EF, Chinchilli VM. Linear and Nonlinear Models for Analysis of Repeated Measures. New York, NY: Marcel Dekker; 1997
25. Borenstein M, Hedges LV, Higgins JPT, et al. Introduction to Meta-Analysis (Statistics in Practice). United Kingdom: John Wiley & Sons; 2009
26. Billingsley P. Probability and Measure. New York, NY: John Wiley; 1986
27. Cox C. Delta method. In: Armitage P, Colton T eds. Encyclopedia of Biostatistics. New York, NY: John Wiley; 1998;1125-1127
28. de Haan L, Lavalaye J, van Bruggen M, et al. Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: Clinical implications. Can J Psychiatry. 2004;49: 290-296
29. Corripio I, Perez V, Catafau AM, et al. Striatal D2 receptor binding as a marker of prognosis and outcome in untreated first-episode psychosis. Neuroimage. 2006;29:662-666
30. WHO Guidelines. Guidelines for ATC Classification and DDD Assignment, 2010. Oslo: 2009
31. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol. 2004;24:192-208
32. Andreasen NC, Pressler M, Nopoulos P, et al. Antipsychotic dose equivalents and dose-years: A standardized method for comparing exposure to different drugs. Biol Psychiatry. 2010;67:255-262
33. Kapur S, Remington G, Jones C, et al. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: A PET study. Am J Psychiatry. 1996;153:948-950
34. Kapur S, Zipursky R, Roy P, et al. The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: A PET study. Psychopharmacology (Berl). 1997;131:148-152
35. Kapur S, Zipursky R, Jones C, et al. A positron emission tomography study of quetiapine in schizophrenia: A preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry. 2000;57:553-559
36. Pilowsky LS, Costa DC, Ell PJ, et al. D2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. An 123I-IBZM single photon emission computerised tomography study. Br J Psychiatry. 1994;164:16-26
37. Catafau AM, Suarez M, Bullich S, et al. Within-subject comparison of striatal D2 receptor occupancy measurements using [123I]IBZM SPECT and [11C]Raclopride PET. Neuroimage. 2009;46:447-458
38. Erlandsson K, Bressan RA, Mulligan RS, et al. Analysis of D2 dopamine receptor occupancy with quantitative SPET using the high-Affinity ligand [123I]epidepride: Resolving conflicting findings. Neuroimage. 2003;19:1205-1214
39. Olsson H, Farde L. Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancyVa simulation study based on experimental data. Neuroimage. 2001;14:936-945
40. Kapur S, Zipursky RB, Jones C, et al. The D2 receptor occupancy profile of loxapine determined using PET. Neuropsychopharmacology. 1996;15:562-566
41. Takano A, Suhara T, Ikoma Y, et al. Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. Int J Neuropsychopharmacol. 2004;7:19-26
42. Hirvonen J, van Erp TG, Huttunen J, et al. Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. Arch Gen Psychiatry. 2005;62:371-378
43. APA. Practice Guidelines for the Treatment of Psychiatric Disorders: Compendium, 2nd Edition. Arlington, VA: American Psyhiatric Publishing; 2006
44. Meltzer HY, Huang M. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res. 2008;172:177-197